Two departments have issued "Several Measures to Support the High-Quality Development of Innovative Drugs" to support the use of medical insurance data for the research and development of innovative drugs.

Today, the National Healthcare Security Administration and the National Health Commission issued the "Measures to Support the High-Quality Development of Innovative Drugs," which proposed supporting the use of healthcare security data for the research and development of innovative drugs. Strengthening the interoperability and coordination of information among medical, healthcare security, and pharmaceutical sectors, managing healthcare security data resources well, and promoting the utilization of public data resources in the healthcare security field. On the basis of ensuring data security, legality, and compliance, exploring providing necessary healthcare security data services for the research and development of innovative drugs. Relying on the national unified healthcare information platform, collecting and analyzing data on disease spectrum and clinical drug demands, developing data products tailored to the requirements of innovative drug research and development, supporting pharmaceutical companies, research institutions, medical facilities, etc., to rationally determine research and development directions, layout research and development pipelines, and enhance innovation efficiency. It also proposed encouraging commercial health insurance to expand investment in innovative drugs. Encouraging commercial health insurance companies to provide stable long-term investment for the research and development of innovative drugs through various means such as innovative drug investment funds, nurturing patient capital to support innovative drugs. Furthermore, it emphasized the need to strengthen the guidance on drug catalog entry policies. Optimizing the reception mechanism for enterprises by healthcare security departments, facilitating communication channels between healthcare security departments and innovative drug companies, and enhancing guidance on the entry of innovative drugs into drug catalogs. For innovative drugs whose market applications have been accepted by the national drug regulatory authority, companies can simultaneously apply for policy guidance from healthcare security departments. Healthcare security departments and companies can engage in discussions regarding the main specifications, reference drugs, payment scope, etc., related to drug catalog entry. The full text of the document can be found above.